Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05152524 · ClinicalTrials.gov registry record · NA

Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever

A NA study of Ischemic Stroke and Neovascularization, sponsored by Rapid Medical.

Active
Registry status
NA
Development phase
168
Enrollment target
20
Study locations

NCT05152524 is a NA study of Ischemic Stroke and Neovascularization that is active but no longer recruiting, run by Rapid Medical. The registered enrollment target is 168 participants, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05152524, a NA study of Ischemic Stroke and Neovascularization, is active but no longer recruiting, sponsored by Rapid Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
168 participants
Enrollment target
20
Study locations

Study Summary

The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.

Conditions Studied

Ischemic Stroke Neovascularization

Interventions

  • DEVICE Tigertriever 13

Study Locations (20)

Other

  • CUB Hôpital Erasme - Brussels
  • Universitätsklinikum Bonn - Bonn
  • Alfreid Krupp - Essen
  • Universitätsklinikum Schleswig-Holstein - Kiel
  • St. Lukas hospital, Radprax - Solingen
  • Orebro University Hospital - Örebro

New York

  • University of Buffalo - Buffalo
  • NYU Langone Health - New York
  • Mount Sinai - New York
  • Stony Brook University - Stony Brook

California

  • Lakewood Regional Medical Center - Los Angeles
  • Los Robles - Thousand Oaks

Michigan

  • Corewell Health (Spectrum) - Grand Rapids
  • Munson Medical Center - Traverse City

Texas

  • Valley Baptist Medical Center - Harlingen
  • Texas Stroke Institute - Plano

Georgia

  • WellStar Research Institute - Marietta

Illinois

  • Advocate Aurora Research Institute, - Chicago

Ohio

  • Mercy Health - Toledo

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2022-03-25
Est. Completion 2026-03
Phase NA

Sponsor

Rapid Medical

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05152524

The ClinicalTrials.gov registry entry for NCT05152524 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (89% lower). The listed sponsor is Rapid Medical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Tigertriever 13 is the first listed.

NCT05152524 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, California.

Frequently Asked Questions

What is clinical trial NCT05152524 about?

NCT05152524 is a clinical study titled "Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever". The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological defi...

What is the current status of trial NCT05152524?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 168 participants. The study started on 2022-03-25. Estimated completion is 2026-03.

What conditions does trial NCT05152524 study?

This clinical trial studies the following conditions: Ischemic Stroke, Neovascularization.

What interventions are being tested in trial NCT05152524?

The interventions under investigation include: Tigertriever 13 (DEVICE).

Who is sponsoring clinical trial NCT05152524?

This trial is sponsored by Rapid Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05152524 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ischemic Stroke

All registered trials for this condition

Neovascularization

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.